The eliquis market in Europe is expected to reach a projected revenue of US$ 5,557.2 million by 2033. A compound annual growth rate of -2.6% is expected of Europe eliquis market from 2025 to 2033.
In terms of revenue, Europe region accounted for 30.7% of the global eliquis market in 2024.
Globally, North America is projected to lead the regional market in terms of revenue in 2033.
Asia Pacific is the fastest growing regional market and is projected to reach USD 5,019.3 million by 2033.
Europe represents a significant region in the global Eliquis (apixaban) market due to its structured healthcare systems and rising cardiovascular disease burden. Countries across the region have incorporated DOACs into national treatment protocols, reinforcing Eliquis adoption. Clinical outcomes showing reduced bleeding risks and high efficacy have driven prescribing trends.
The availability of cardiology specialists and integrated care models has enhanced treatment continuity. Market expansion is also supported by streamlined reimbursement pathways and expanding hospital formularies. As populations age, the need for stroke and clot prevention therapies is steadily increasing.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Eliquis Market Outlook will help companies and investors design strategic landscapes.
Atrial Fibrillation (Af) was the largest segment with a revenue share of 61.57% in 2024.
Horizon Databook has segmented the Europe eliquis market based on atrial fibrillation (af), deep vein thrombosis (dvt), pulmonary embolism (pe), post-operative vte prophylaxis (at-risk cases) covering the revenue growth of each sub-segment from 2021 to 2033.
Europe represents a significant region in the global Eliquis (apixaban) market due to its structured healthcare systems and rising cardiovascular disease burden. Countries across the region have incorporated DOACs into national treatment protocols, reinforcing Eliquis adoption. Clinical outcomes showing reduced bleeding risks and high efficacy have driven prescribing trends.
The availability of cardiology specialists and integrated care models has enhanced treatment continuity. Market expansion is also supported by streamlined reimbursement pathways and expanding hospital formularies. As populations age, the need for stroke and clot prevention therapies is steadily increasing.
Europe Eliquis Market Indication Outlook (Revenue, USD Million , 2021-2033)
Atrial Fibrillation (AF)
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Post-Operative VTE Prophylaxis (at-risk cases)
Others
Europe Eliquis Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Reasons to subscribe to Eliquis Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Eliquis Market Outlook databook
Our clientele includes a mix of Eliquis Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe Eliquis Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe Eliquis Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.